Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP, close the discussion with key takeaways for payers to consider related to ruxolitinib and insights on future research.
The Role of Pharmacogenomics in Reducing Racial Disparities in Pediatric AML Treatment Outcomes
May 20th 2024A new study in JAMA Network Open suggests that disparities in outcomes between Black and White children with acute myeloid leukemia may be due to differences in pharmacogenomics, which is how genes affect drug responses.
Read More